Vitamin supplementation as a potential adjunctive therapeutic approach for COVID-19 : biological and clinical plausibility
© 2021 Walter de Gruyter GmbH, Berlin/Boston..
The recent pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19) has introduced itself into the human population in the 21st century after the coronavirus diseases SARS-CoV and Middle East respiratory syndrome (MERS-CoV). Major investigations are underway worldwide in the search for pharmaceutical interventions for COVID-19 and many agents are administered in off-label routes. Several cases are under study to check or restrict clinical manifestations of COVID-19. According to the fact that the efficacy of some micro-nutrients like vitamins is proven to treat or prevent infectious diseases because of their antimicrobial and immunomodulatory activity, the potential role of vitamins in the COVID-19 treatment or prevention must be considered.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Journal of basic and clinical physiology and pharmacology - 33(2021), 1 vom: 09. Aug., Seite 55-77 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Daei Sorkhabi, Amin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 09.02.2022 Date Revised 07.12.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1515/jbcpp-2021-0111 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32924082X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32924082X | ||
| 003 | DE-627 | ||
| 005 | 20231225204704.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/jbcpp-2021-0111 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1097.xml |
| 035 | |a (DE-627)NLM32924082X | ||
| 035 | |a (NLM)34380185 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Daei Sorkhabi, Amin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vitamin supplementation as a potential adjunctive therapeutic approach for COVID-19 |b biological and clinical plausibility |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.02.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 Walter de Gruyter GmbH, Berlin/Boston. | ||
| 520 | |a The recent pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19) has introduced itself into the human population in the 21st century after the coronavirus diseases SARS-CoV and Middle East respiratory syndrome (MERS-CoV). Major investigations are underway worldwide in the search for pharmaceutical interventions for COVID-19 and many agents are administered in off-label routes. Several cases are under study to check or restrict clinical manifestations of COVID-19. According to the fact that the efficacy of some micro-nutrients like vitamins is proven to treat or prevent infectious diseases because of their antimicrobial and immunomodulatory activity, the potential role of vitamins in the COVID-19 treatment or prevention must be considered | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a immunomodulatory functions | |
| 650 | 4 | |a prophylaxis | |
| 650 | 4 | |a treatment | |
| 650 | 4 | |a vitamins | |
| 650 | 7 | |a Vitamins |2 NLM | |
| 700 | 1 | |a Sarkesh, Aila |e verfasserin |4 aut | |
| 700 | 1 | |a Daei Sorkhabi, Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Entezari-Maleki, Taher |e verfasserin |4 aut | |
| 700 | 1 | |a Rashedi, Jalil |e verfasserin |4 aut | |
| 700 | 1 | |a Bannazadeh Baghi, Hossein |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of basic and clinical physiology and pharmacology |d 1997 |g 33(2021), 1 vom: 09. Aug., Seite 55-77 |w (DE-627)NLM012656321 |x 2191-0286 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2021 |g number:1 |g day:09 |g month:08 |g pages:55-77 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1515/jbcpp-2021-0111 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2021 |e 1 |b 09 |c 08 |h 55-77 | ||